Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into an agreement to divest a selection of non-core products from the company’s portfolio sold in Latin America, 17 September 2021
Today, the European Commission is launching the European Health Emergency preparedness and Response Authority (HERA) to prevent, detect, and rapidly respond to health emergencies. 16 September 2021
The US regulator has granted approval for a first-in-class oral tyrosine kinase inhibitor (TKI) developed by Japanese pharma major Takeda Pharmaceutical. 16 September 2021
French privately-held pharma major Servier and Neurochlore have recently announced that, following a lack of efficacy in two Phase III trials of bumetanide for autism spectrum disorder (ASD) in adolescents, they would be terminating these trials early. 16 September 2021
Adding to the positive current data, US healthcare giant Johnson & Johnson today announced new results for its Ebola vaccine, which received European marketing authorization in July 2020. 15 September 2021
At the 2021 European Society of Cardiology (ESC) Congress, full results were presented for EMPEROR-Preserved, a Phase III trial investigating US pharma major Eli Lilly and family-owned German drugmaker Boehringer Ingelheim’s Jardiance (empagliflozin) in heart failure with preserved ejection fraction (HFpEF). 15 September 2021
USA-based Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients’ lives. 14 September 2021
New Jersey, USA-based precision medicine company Nuvectis Pharma has licensed exclusive worldwide rights to a novel small molecule being developed by the University of Edinburgh, in the UK. 14 September 2021
Binnopharm Group, a Russian pharmaceutical producer will invest more than 2.5 billion roubles ($33 million) in the development of new drugs within the next several years, according to the company which was launched in February this year. 14 September 2021
Ireland-headquartered fish oil-based heart drug specialist Amarin Corp has announced the first European launch of Vazkepa (icosapent ethyl) in Germany. 14 September 2021
UK endocrine diseases specialist Diurnal Group today announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the UK as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). 13 September 2021
British drug developer Nuformix (LSE: NFX) leapt 19.3% this morning, after it announced the signing of an exclusive global licensing agreement with fellow UK-based Oxilio, a privately held pharmaceutical development company, for NXP001 (a proprietary new form of aprepitant) for oncology indications. 13 September 2021
Prices for brand-name drugs in particular are higher in the USA compared with other high-income countries, most of which regulate drug prices. However, inconsistent availability of data on net prices (ie, prices after rebates and other discounts) complicates international comparisons of drug prices, according to new research. 13 September 2021
Sumitomo Dainippon Pharma has launched Twymeeg (imeglimin hydrochloride) in Japan, the first launch of the diabetes drug anywhere in the world. 10 September 2021
US Health and Human Services (HHS) Secretary Xavier Becerra yesterday unveiled a comprehensive plan to lower drug prices as part of a long-awaited report from the HHS to the White House that offers a wide-ranging series of recommendations on curbing rising drug costs 10 September 2021
Shares Ireland-incorporated Endo International rose almost 18% to $2.10 in after-hours trading yesterday, after the company announced a $50 million settlement to exit a New York opioid trial. 10 September 2021
Zambon, a privately-owned Italian pharmaceutical company, has presented positive final results from the Phase III PROMIS-I study at the European Respiratory Society (ERS) Annual Meeting. 9 September 2021
French privately-held pharma major Servier and Neurochlore have announced that no sign of effectiveness was observed in their two Phase III clinical studies assessing bumetanide versus placebo in the treatment of autism spectrum disorders (ASD) in children and adolescents. 9 September 2021
Swiss pharma giant Roche has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of German biotech TIB Molbiol Group. 9 September 2021
Positive high-level results have been released from the MANDALA and DENALI Phase III trials of PT027 (albuterol/budesonide), at both 180/160mcg and 180/80mcg doses, showing the meeting of all primary endpoints and demonstrating statistically-significant benefits in patients with asthma versus individual components albuterol, also known as salbutamol (180mcg) and budesonide (160mg). 9 September 2021